<DOC>
	<DOCNO>NCT00603590</DOCNO>
	<brief_summary>Cardiovascular major cause mortality Iran , account 45.7 % death . In Golestan ( North Eastern Iran ) preliminary finding follow-up Golestan Cohort consistent national figure : 45 % ( least 22 48 death ) death attribute cardiovascular event . Cardiovascular diseases become increase problem Iranian population age . In 2003 Law Wald propose prevention cardiovascular disease use fixed-dose combination therapy combine antihypertensive , lipid lower antiplatelet drug single preparation . They propose treatment offer person high risk cardiovascular disease whether elevate blood pressure elevate serum lipid concentration . This pilot study aim investigate safety efficacy fixed-dose combination therapy two antihypertensive drug , aspirin atorvastatin population would currently consider eligible antihypertensive treatment lipid lower treatment . Methods : This double-blind randomized control trial . The intervention group assign take tablet consist single daily tablet comprise Aspirin 81mg , Hydrochlorothiazide 12.5mg , Enalapril 2.5mg Atorvastatin 20mg . The control group assign identical placebo . The population study include men age 50 80 ( inclusive ) woman age 55 80 ( inclusive ) currently eligible take antihypertensive lipid lower therapy . Persons find baseline blood pressure &gt; 160/100 mm Hg , total cholesterol &gt; 240mg/dL , exist cardiovascular disease take antihypertensive ore lipid lower therapy exclude . It intend randomize follow 500 subject 12 month . The primary outcome purpose sample size calculation change systolic blood pressure . Additional outcome include change diastolic blood pressure , change LDL cholesterol occurrence adverse event .</brief_summary>
	<brief_title>Phase II Study Heart Polypill Safety Efficacy Primary Prevention Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criterion All men 50 80 woman 55 80 resident Kalaleh , Golestan , least one year . Exclusion criterion Existing cardiovascular disease ( stroke , transient ischaemic attack , myocardial infarction angina ) Already take antihypertensive drug , aspirin statin Already clinical indication treatment antihypertensive drug , aspirin statin . Blood pressure &gt; 160/100 mm Hg Total Cholesterol &gt; 240 mg/dL ( LDL &gt; 190 mg/dL ) Probable diabetes : HbA1c &gt; 6.0 Contraindication component Polypill Contraindications aspirin Previous history allergy aspirin History peptic ulcer bleed whole life endoscopic evidence peptic ulcer within past 3 month Contraindications statins Liver failure Contraindications blood pressure lower Systolic blood pressure ≤90 mm Hg diastolic blood pressure ≤70 mm Hg Symptomatic postural hypotension Difference mean seat BP stand BP great 20 mm Hg Contraindications thiazide Uric acid &gt; 8 men uric acid &gt; 6 woman / gout ( ~10 % ) Creatinine &gt; 1.2 mg/dl Other predominant medical problem may limit compliance study treatment include : History alcohol abuse : 60cc woman 80cc men History drug abuse : IV drug abuser eat smoke 4 time week Limiting psychiatric illness ( eg : mania , schizophrenia , severe depression , psychosis dementia ) Limiting physical disability sufficient prevent subject walk Other lifethreatening condition cancer</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cardiovascular disease</keyword>
	<keyword>primary prevention</keyword>
	<keyword>Polypill</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>ADR</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Adherence</keyword>
	<keyword>Compliance</keyword>
</DOC>